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Acquired traiHuman neurological disorders include a wide range of illnesses which have a disproportionately high
prevalence in the increasingly populous geriatric community. Any research effort directed at discovering the
aetiology of neurological disease is greatly enhanced with in vivo models of the disease of interest. Scientiﬁc
research incorporating the use of mice has advanced rapidly in the last three decades. Relatively simple to
breed, maintain and train, mice have many advantages over other species for use in research. More than a
century of selective breeding has provided investigators with a rich gene pool and sub-strain diversity from
which to choose for their research. Thus the dramatic increase in genetic screening and gene engineering
that has occurred in research in recent decades has enabled the generation of a multitude of mouse models.
This review discusses the relative utility of mouse models in which a heritable or non-heritable (acquired)
manipulation has been used to model a speciﬁed trait of a human neurological disorder. The techniques used
in deriving useful genetic alterations or modiﬁcations and in generating acquired mouse models are outlined
with examples of each provided.lsevier B.V.© 2010 Published by Elsevier B.V.1. Introduction
Several human neurological disorders that we recognise today were
initially identiﬁed and described many decades ago. For example, Alois
Alzheimer ﬁrst published his ﬁndings in 1906 [1], George Huntington
ﬁrst characterised the disease to bear his name in 1872 [2] and James
Parkinson ﬁrst described “A shaking Palsy,” which came to known as
Parkinsonism in 1817 [3]. These three illnesses represent common
forms of inherited neurological disease however this review will also
include other neurological disorders, deﬁned as an illness of the nervous
system. Use of the termmodel is deﬁned as a systemwhereby a therapy
can be tested. The common house mouse (Mus muscularis) has a
genomewith 97% homology to the human genome. It is small and easily
maintained in a research services facility. It breeds well with a short
gestation period and is amenable to training and testing in many in vivo
assays. Mice have been selectively bred for features such as coat colour
and for scientiﬁc research. This work was started over 100 years ago by
mouse fanciers such as Abbie Lathrop and by researchers such as
William Castle, a Harvard geneticist. This history of selective breeding
has provided scientiﬁc investigatorswith awide variety of strains to use
for their research. Despite this apparent range of phenotypes, a study of
8.7million single polynucleotidepolymorphisms of inbredmouse strain
revealed a surprisingly low level of genetic variability among the four
main inbred mouse stains and among the original wild type mousestrains [4]. Following on from these pioneers, standardisation of the
supply ofmice to the research communitywas increasedwhen Clarence
Little opened the Jackson Laboratories in 1929 to become a world-wide
resource formouse research scientists [5].With these resources and the
complete sequencing of the mouse genome [6], the common house
mouse has become the species of choice for researchers where
mammalian genetic manipulation is required and, with approximately
25millionmice used in research laboratories around theworld, they are
the most common research mammal. This review describes how the
mouse can be used to generate models of neurological disorders via
genetic and non-genetic manipulations with a description of the
techniques used to create selected models. The pros and cons of using
the mouse as a species in which to model neurological disorders are
highlighted. Not every disorder or model is covered as there are too
many to include in one review, however representative examples are
provided. There is an emphasis on genetically engineeredmodels as the
mouse does occupy a place of importance in this technology since few
mammalian laboratory species are amenable to such genetic engineer-
ing, whereas many different laboratory species can be used to provide
other, non-genetic, types of model.
Mouse models of neurological disorders can be usefully divided into
whether or not the model is heritable. Human neurological disorders
with a mutant gene component make ideal candidates for modelling via
gene manipulation. It follows then that human neurological disorders
with an identiﬁed underlying genetic component, for example Alzhei-
mer's disease, have been extensively modelled using genetically
manipulated mouse models. Alternatively an interesting neurological
phenotypemay be identiﬁed as a result of a spontaneousmutation in the
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spontaneous mutant mouse models are then bred to sustain the
appropriate phenotype of interest. Clearly neurological disorders also
have heritable traits that donot includemutant gene components but are
well characterised risk factors for the disorder, for example the Apoe4
allele inAD.As these traits canbe inherited fromgeneration togeneration
they can also included as heritable trait models. Mouse models that do
not carry a heritable component are focussed on replicating a phenotype
characteristic of the relevant disorder. Thosehumandisorders that donot
have a deﬁned genetic component, or in which a complex multi-gene
interacting system is under investigation, are more readily modelled
using non heritable mouse models that have an identiﬁed robust
phenotype and are acquired by physical manipulation.
While mice have come to be used as an invaluable tool to generate
models of human disorders and elegant mouse models can reproduce
numerous aspects of a human disease it should be realised that, by their
very naturemousemodels are excellent tools to examine the function of
a particular aspect of a human disorder in the context of a mouse. As
such they will never be able to reproduce the full phenotype of any
human disorder and the disease relevance of the model should not be
overstated [8]. However if used in appropriate context they have the
power to help unravel complex biochemical and behavioural pheno-
types aswell as evaluate the effect of potential therapeutic interventions
that are impossible to investigate otherwise.Onedisease areawhereany
pre-clinical model will fail to replicate the human condition is where
speciﬁcally human characteristics are involved, for example in the vocal
descriptions of feeling, hallucinations and delusions manifest in mental
illnesses. In such examples the disorder can be broken down into
speciﬁc component phenotypeswhich aremore amenable tomodelling
in mice.
Genetically manipulated mouse models model are generated by
genetic engineering of themouse genome in order to produce a desired
protein expression proﬁle. This proﬁlemay involve temporal and spatial
control of the gene transcription to realise the relevant protein
expression. The murine host genome is manipulated by one of two
general methods which result in elevated or suppressed protein
expression. Elevated protein expression can be achieved by direct
micro-injection of a gene construct comprising a modiﬁed complimen-
taryDeoxyribonucleic acid (cDNA) gene sequence (transgene) into host
single cell mouse embryos. These transgenes often carry one or several
mutations identiﬁed with a particular disorder and their expression
under the control of a speciﬁc promoter. Protein expression can be
eliminated by the “knockout” of a gene by replacing a key sequence of
the host genome with a sequence of irrelevant DNA into the loci of a
targeted gene thus interfering with the gene transcription. This
manipulation is carried out in genomic host DNA using homologous
recombination in embryonic stem cells and subsequent introduction
intohostmulti-cellular blastocystmouseembryos. These techniques are
well established (see [9] for detailedmethods) and have been in use for
almost three decades. Initially this technology was limited to simple
overexpression or knockout of a gene of interest however the
technology has developed to allow temporal and spatial control of the
gene manipulation with elegant tissue restricted expression of the
genetic construct. In additiongenetically engineered sequencesof target
genes of interest may be used as the irrelevant DNA in knockout mouse
models, thus generating the “knockin”mouse model. Once successfully
generatedandbred true, geneticallymanipulatedmousemodelsmaybe
interbred to produce all manner multiple gene mouse models.
A further approach relies on random mutagenesis rather than
targeted genemanipulation. Geneticallymodiﬁed animals derived from
these breeding programs are often discovered by phenotypic screens of
thousands of mice. Spontaneous mutations have arisen in the research
mouse population and these have been selectively bred to provide
interesting mouse models. A good example of this is the Stargazer
mouse model, used in epilepsy research, discovered at the Jackson
Laboratory in 1979. Following phenotypic characterisation, whereabnormal, jerky head movements were observed, the model was
found to have a mutation in gamma subunit 2 of the voltage dependant
calcium channel gene on chromosome 15 [7]. Useful spontaneous
mutations are rare and attempts have been made to accelerate this
mutagenesis with speciﬁc breeding colony experiments. One such
example is the N-ethyl-N-nitrosourea (ENU) mutagenesis project [10].
This project makes use of the mutagenic properties of the ENU to
introduce germ line mutations by direct intraperitoneal injection into
foundermice. Once offspring derived from breeding these foundermice
are screened for phenotypic abnormalities using a platform phenotype
assessment and mice with interesting phenotypes are selectively bred
to expand the new genetically altered line for further characterisation.
While many mouse models have a genetic component and as such
have a direct link to the underlying genetic component of the disease
that they are designed to represent, mouse models of neurological
disorders can also be generated from pharmacological or mechanical
manipulations. This approach has no heritable component and relies on
an understanding of the biochemical pathways that are disturbed in the
relevant disorder. A major advantage of this approach is the relative
speed atwhich amodel can be generated usingwild typemice available
from commercial suppliers. In addition extensive mouse breeding
regimes are not required and the cost of generating geneticallymodiﬁed
mouse models de novo or in-licensing them is obviated.
2. Heritable mouse models
A multitude of genetically altered (GA) mouse models of
neurological disorders have been generated and various institutes
maintain databases of the mouse model available via the World Wide
Web (for examples see ([11–15]). Many articles have been published
reviewing the current research efforts into a number of neurological
disorders. Select reviews of models of Alzheimer disease [16] ,
Parkinson's disease [17] , Huntington's disease [18] , Tauopathies [19]
Amyotrophic Lateral Sclerosis [20] , Friedreich's ataxia [21] and
Duchenne Muscular Dystrophy [22] exemplify useful literature
sources of information to gain an in depth understanding of current
mouse models of a disorder of interest. This resource is a valuable
addition to any researcher seeking to investigate the genetics of a
particular disorder. It is clear however that the diverse range of
phenotypes seen in mouse models developed from acquired rather
than inherited characteristics means the review literature is not easily
classiﬁed by disease and as such publications are limited.
2.1. Overexpression of a transgene
A simple transgenic mouse model is generated when a transgene
construct is introduced into themouse genome and is inherited through
generations of mice. The transgene is introduced into the mouse
genome by micro-injection of a puriﬁed fragment of the engineered
DNA into the male pronucleus of a single cell mouse embryo (Fig. 1a)
through a very ﬁne glass needle. Following injection the transgene is
inserted into the mouse genome when the embryo undergoes mitosis.
Embryos surviving this injection are transferred into the infundibulum
of a pseudo-pregnant recipient dam and allowed to develop to term.
Founder offspring are genotyped for incorporation of the transgene and
positive transgenic mice are bred to wild type mice to further expand
the colony for subsequent experimentation. The transgene comprises a
complimentary DNA (cDNA) sequence encoding the gene of interest
driven by a promoter directing expression to the desired tissue. In order
to generate a transgenic model of a heritable disease, the cDNA should
carry a mutation linked directly to the human disease. The choice of
promoter is dictated by the pathological features of the disease being
modelled. Many promoters are available with well characterised tissue
and cell type distribution to which they drive the transgene expres-
sion [23] however many confounding factors such as integration site,
copy number andmouse strain need to be considered. A comprehensive
Fig. 1.Methods of generating genetically modiﬁed mouse models. (a) Schematic representation of three types of transgene construct used to generate transgenic mouse models by
microinjection into the male pronucleus of a host single cell embryo. The dotted line represents expansion of the pronucleus on injection of the construct. (i) GOI+reporter fusion
protein construct, (ii) simple GOI construct, (iii) GOI and reporter generated independently using an IRES element. (b) Schematic representation of the steps used to generate
knockout or knockin mouse models. The endogenous GOI is disrupted with an exogenous IVS, incorporated into the genome of an embryonic stem cell by HR and appropriately
targeted clones are injected into the blastocoel of a host blastocyst where they adhere to the inner cell mass and are incorporated into the soma. Abbreviations: GOI: gene of interest;
IRES: internal ribosomal entry site; I-P: isolate and purify; FS: ﬂanking sequence; HR: homologous recombination; Seln: Selection with positive and negative markers; IVS:
intervening sequence; ES cells: embryonic stem cells.
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researchers as different promoters may produce different distribution
patterns in different models. As such transgenic lines need to be
investigated in isolation and characterised as such.
One disease that has been a rich source of transgenic mouse models
is Alzheimer's disease (AD). While the majority of AD patients are
sporadic cases and have no observed heritable genetic component, a
minority of patients do have heritable forms of the disease. These
inherited forms include mutant genes as well as complex genetic traits
that increase the likelihood of developing AD and both have provided
researchers with invaluable tools to investigate the disease pathology.
Using this genetic link many mouse models of different aspects of AD
have been generated. A key pathological lesion in the brains of AD
patients is the Amyloid plaque which is derived from pathological
cleavage of the amyloid precursor protein (APP) by β- and γ-secretase
enzymes. While a wide range of currently available AD mouse models
now exists (reviewed in [16]) using a variety of genetic manipulation
techniques (described below), simple transgenic mouse models of AD
have proved to be useful tools to investigate disease pathology. Mouse
models incorporating only APP are not models of AD, indeed no mouse
model can fully replicate all facets of a human condition such as AD,
though they do reproduce key features of the disease [24,25]. One early
example of such a model is the PDAPP mouse in which numerous
features of AD were reproduced including neuritic plaques, synaptic
loss, astrocytosis and microgliosis [26]. This model has cDNA encoding
the Amyloid Precursor Protein (APP) carrying the APPV717F (Indiana)
mutation drivenby the platelet derived growth factor (PDGF) promoter.
Direct injection of this transgene into a single cell embryo led to the
development of amyloid plaques and a number of phenotypes
characteristic of AD including cholinergic neuropathy [27], behavioural
disturbances [28] and age related learning deﬁcits [29] that may be
explained by decreased hippocampal neurogenesis [30]. While loss of
synaptic and dendritic proteins was seen, no neuroﬁbrillary tangles
could be detected [31], suggesting APP alone is not sufﬁcient to produce
neurodegeneration but that amyloid pathology may occur prior to tau
pathology and frank neurodegeneration as outlined in the amyloid
cascade hypothesis [32]. The elevated levels of soluble Αβ generated inthe PDAPPmousemodel not only enter the plasma but also deposit into
amyloid plaques thus revealing a plaque-associated disruption of the
CSF and plasma Αβ dynamic equilibrium [33]. This conﬁrmed that
peripheral sequestration of the elevated levels of Αβ would modulate
the deposits of amyloid plaque [34]. The PDAPPmousemodel replicates
key pathological features seen in AD andhas clear utility as a pre-clinical
model of the amyloidogenic elements of the disease.
Further key features of the transgene construction may include
regulatory elements that repress and/or enhance transgene expres-
sion and a reporter gene to allow spatial tracking of the transgene
expression. The minimal regulatory elements required for accurate
transgene expression can be conﬁrmed in vitro. This is done by
inserting the transgene into an appropriate neuronal cell line and
screening the cell line for expressed protein of interest. In this way the
transgene can be engineered to include or exclude speciﬁc gene
sequences that regulate the transgene expression to give the desired
expression pattern. The reporter gene can be engineered as a fusion
protein with the protein of interest, allowing tracking of endogenous
transcriptional activity [35] and faithfully replicating spatial expres-
sion patterns. A problem with this approach is tagging a transgene
with a reporter gene may impact on the protein function and so
independent reporter expression can be achieved with an Internal
Ribosomal Entry Site (IRES) element. This DNA sequence recruits the
nuclear ribosomal machinery to transcribe downstream DNA but is
under control of a promoter sequence upstream in the transgene
construct. In this situation two gene transcripts are produced from
one promoter and so a reporter protein is produced in that will not
interfere with the function of the protein of interest while enabling
spatial expression patterns to be followed [36].
Many transgenic models of Alzheimer disease have been generated
incorporating APP familial mutations that replicate key clinical features
of thedisease pathology.A limitednumberof genes that carrymutations
linked to AD have been discovered, one of which is the presenilin gene
[37]. Presenilin is a component protein of the γ-secretase enzyme
which, along with the β-secretase enzyme, cleaves the APP protein to
liberate the amyloid protein fragment Aβ that aggregates to form the
amyloid plaque lesions found in the brains of AD patients. Transgenic
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increase in brain Aβ42 but limited further AD-related pathology [38].
However when APP and PS1 lines of familial Alzheimer disease mutant
mice are interbred amore aggressivemodel is generated wheremutant
PS1 acts to accelerate the AD phenotype [39]. An even more rapid
acceleration of plaque development was revealed in a quintuple gene
transgenic mouse model [40] showing multiple mutations as well as
multiple transgenes can model the required clinical feature. These
mouse models which carry multiple transgenes and/or mutations do
provide useful laboratory tools to investigate AD pathology but cannot
be considered to accurately reﬂect AD as thesemultiple genemutations
have not been discovered in the human patient population.
These simple and compound transgenic lines of mice all model one
neuropathological lesion found in AD, namely the amyloid plaque.While
some signs of neurodegeneration have been found in thesemodels, frank
neuronal cell loss and reduced brain volume were only successfully
modelled when another key pathological lesion of AD, neuroﬁbrillary
tangles (NFTs), was generated by expressing mutated microtubule
associated tau (MAPT or Tau) [41]. A triple transgenic mouse model
linking the mutant APP, PS1 and Tau genes has been developed and was
used to clarify the relationship between Αβ, synaptic dysfunction and
tangles providing a useful insight into these clinical features of AD and
strong support for the amyloid cascade hypothesis [42] whereby amyloid
pathology precedes Tau pathology NFT and subsequent neuronal loss.
Alzheimer's disease has several mutant genes linked to the disease
pathology however no single mutant mouse model of these genes is
able to reproduce the full disease phenotype. In contrast insertion of
an expanded repeat CAG sequence (approximately 130 repeats) in
Exon 1 of the human huntingtin gene plus part of the huntingtin
promoter was sufﬁcient to produce mouse model with a progressive
neurological phenotype characteristic of Huntington's disease [43].
This R6/2 transgenic mouse model of Huntington's disease is a good
example of a monogenetic mouse model that reproduces most
phenotypes of a neurological disorder. The major phenotypes in this
model are a constant tremor that becomes progressively worse and is
exacerbated by stress during basic husbandry. The mice also exhibit
severe handling-induced epileptic seizures that can last for several
minutes. Through open distribution of this model many researchers
have been able to explore the phenotypes displayed and found, for
example, deﬁcits in striatal based but not hippocampal based learning
[44] and impaired CA3 mossy ﬁbre LTP may contribute to impaired
spatial learning deﬁcits [45].
The introductionofmodiﬁed transgenes into amouse genomeallows
for amultitude ofmousemodels to be generated. A powerful example of
this technology is the solution found when researcher wanted to
overcome the problem of the effect of genetic modiﬁcation during
development in utero. In the transgenicmodels described above, protein
expression is under control of the selected promoter. Many promoters
are active during the development of the embryo in utero and during
post partum maturation. Most neurodegenerative disorders are ob-
served later in life and so expression of the mutant transgene during
early life may have undesirable effects on development. In addition the
facility to switch transgene expression on and off allows for precise
temporal control of the model phenotype. This issue has been resolved
elegantly using tetracycline inducible expression systems [46]. There are
a number of induction systems to control mouse transgene expres-
sion [47]. The tetracycline system has advantages over other systems as
it is reversible and relatively tightly controlled following the develop-
ment of tetracycline controlled transcriptional silencers to eliminate
transgene leakage [48]. A diverse range of transgenes and transgenic
models can be derived from this technology, an elegant example of
which is the Tg4510mousemodel [49]. In this model two separate lines
of mice are used to provide an activator protein in a speciﬁc tissue and a
responder protein driving the gene of interest. The activator in this
system is tetracycline, a broad spectrum antibiotic that prevents protein
synthesis by inhibiting the binding of aminoacyl-tRNA to the mRNA–ribosome complex, ﬁrst demonstrated in mammalian cells [50]. The
activator mouse line has a transcriptional activator (TA) element
comprising the “tet-Off” gene coding sequence under control of the α-
calcium-calmodulin-dependentkinase II (CamK2)promoter. Thesecond
mouse line has expression of a cDNA encoding a P301L Tau mutation
under the control of the tetracycline operon-responsive element (TRE)
(Fig. 2a). When mated together the two single transgene lines combine
to produce bigenic offspringwhereby production of the TA element is in
tissue speciﬁed by the CamK2 promoter (the hippocampus and cortex
[51]) which initiates transcription of the mutant tauP301L transgene.
Activation of the TRE leads to the production of mutant tauP301L protein
(Fig. 2b) and subsequent associated pathology. Further control of this
gene transcription in the Tg4510 bigenic mouse line is by exogenous
dietary supplementof doxycycline. Administration of this semi synthetic
tetracycline antibiotic in thediet of themice acts to effectively ‘switchoff’
mutant tauP301L transgene expression when the dietary doxycycline
binds to the TA element thus preventing binding to the TRE and
subsequentmutant tauP301L proteinproduction. This control is reversible
when doxycycline is removed from the diet the TA element is not longer
bound to doxycycline and is able to bind to the TRE thus initiating
tauP301L transcription (Fig. 2c). The Tg4510 mouse model develops
progressive age-related NFTs, neuronal loss, and behavioural impair-
ments [52]. When doxycycline is introduced into the diet the latter two
phenotypes are ameliorated, however NFTs continued to accumulate.
Thus in the Tg4510 model of tauopathy, neuroﬁbrillary tangles, a key
lesion observed in AD, are not sufﬁcient to cause cognitive decline or
neuronal death [49,53]. Thisﬁnding could have suggested a premier role
for amyloid plaques in the memory loss and neurodegeneration seen in
AD, however subsequentwork on Tg4510model has linked the pre-NFT
accumulation of two oligomeric aggregateswith the pathogenic cascade
in this mouse model [54]. This exquisite control of gene expression
allows for experimental modulation of the phenotype and has led to a
clearer understanding of Tau related disease pathology.
Extending this simple idea, it follows thatusing this bigenic inducible
mouse breeding strategy of separate activator and inducible responder
mouse lines, numerous combinations are possible. When a character-
ised promoter providing expression in the desired tissues is used to
drive expressionof the TAgeneandexpressionof a desiredprotein,with
or without a disease linked mutation, is driven by the TRE then any
protein can by expressed in any tissue for which appropriate promoters
are available. An elegant combination of these technologies is
demonstrated in Krt12rtTA/+/tet-O-LacZ mice which overexpress
reporter genes in a corneal-epithelium–speciﬁc manner when induced
by doxycycline [55]. Previous attempts to produce a corneal-epithelium
speciﬁc mouse model were not successful so in this mouse model a
gene-targeting construct containing an internal ribosomal entry site–
reverse tetracycline transcription activator (IRES-rtTA) cassette was
inserted into the Krt12 allele (keratin 12 gene) to produce a knock-in
(see section 2.3) Krt12rtTA/+ mouse line. The Krt12rtTA/+ knock-in
mice were bred with tet-O-LacZ reporter mice to obtain Krt12rtTA/+/
tet-O-LacZ bi-transgenic mice. The expression of the LacZ gene was
induced in bi-transgenic mice by administration of doxycycline in the
drinking water and chow. Validation of the desired expression pattern
was demonstrated and the mouse model was employed to elucidate
signalling pathways of various growth factors, cytokines and gene
functions in the maintenance of homeostasis and pathogenesis in the
adult mouse cornea. The model serves as an example of a genetically
engineered mouse that is far removed from the wild type genome and
yet is healthy and fertile and provides a valuable mouse model.
2.2. Knockout of an endogenous gene
A gene of interest is effectively ‘knocked out’ by interfering with gene
transcription leading to an inoperative protein. The formation of a
completely inoperative protein is a key consideration when designing a
cloning strategy to knockout a gene of interest. To be most effective the
Fig. 2. Schematic representation of steps required to generate a bigenic mouse model using the tetracycline “off” controlled expression system. (a) Separate mouse lines carrying
activator and responder elements. (b) GOI switched on. Bigenic mouse model in which protein generated by expression of the TA binds to the TRE leading to transcription of the GOI.
(c) GOI switched off. Exogenous doxycycline binds to the TA stopping transcription of the GOI. Abbreviations: TA: transcriptional activator; GOI: gene of interest; TRE: tetracycline
responsive element; Dox: doxycycline.
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possible, preferable replacing Exon 1 of the genomic clone. In this way a
truncated endogenous protein, which may have some partial function
when translated, is less likely to be produced and thus lead to a partial
gene knockout. Any sequence of DNA can be used to interfere with
transcriptionof theexogenousgene locusbut oftena reporter gene is used
as this allows the spatial distribution of the targeted gene to be followed.
After the targetedgenehasbeenappropriately engineered theentire locus
is incorporated into the host genome of embryonic stem (ES) cells by
homologous recombination. In order to increase the likelihood of a
successful recombination approximately 2 kilobases of ﬂanking genomic
sequence is included on either side of the engineered DNA. Additional
DNA sequences are used to allowpositive and negative selection of ES cell
clones. Examples of this may include insertion of the neomycin antibiotic
resistance gene within the ﬂanking genomic sequence as a positive
selectionmarker and insertion of the gene encoding the thymidine kinase
(TK) enzyme. These elements allow for positive selection of clones when
the ES cells are treated with antibiotics, those that have successfully
recombined to include the targeted gene will resist the antibiotic and
survivedue to thepresenceof theneomycin resistancegenebut those that
have not will die. Similarly those clones that have recombined at the
correct place to include the targeted gene but exclude peripheral DNA
sequences and the TK gene will live when treated with the antiviral pro-
drug ganciclovir as it is phosphorylated by TK to produce toxic tripho-
sphates which kill the ES cell clone.
Accurately targeted ES cell clones are cultured to a uniform colony
of single cells which are collected into a hollow needle and injected
into the blastocoel of a host mouse blastocyst (Fig. 1b) where they
adhere to the inner cell mass and subsequently integrate into thebody. Once recovered from the injection the blastocysts are inserted
into the uterus of a recipient dam for gestation. If the coat colour of the
recipient strain is different to that of the ES cell clones (for example
black C57Bl/6 and agouti 129 Sv) then when mature, the male
offspring founder mice with approximately 50% black coat colour are
mated to females to produce the ﬁrst generation of mice. This
percentage of coat colour minimises the contribution of the 129
background strain leading to weak, runt animals that will not breed
well, while maximising the chances of selecting a male founder with
germ line transmission. Tail tissue samples are collected from this ﬁrst
generation and analysed for the correct genotype. Mice possessing
heterozygous copies of the gene are then interbred to generate
homozygous mutant mice to enable full expression of the engineered
gene locus.
Knockout technology is commonly used to evaluate the function of
a gene of interest by removing it and testing the knockout mouse
model in relevant assays. An obvious phenotype resulting from gene
knockout is embryonic lethality. If the gene of interest is essential
during mouse development then removing it will cause embryo
fatality. This may be overcome by combining knockout technology
and an inducible expression system. This was used to good effect
when investigating Presenilin 1 (PS1) gene knockout mice. PS1
knockout mice die shortly after birth due to skeletal and CNS defects
[56]. This prevented the study of PS1 knockout in adult mice so a
conditional PS1 KO (cKO) mouse model was developed with PS1
inactivation restricted to the postnatal forebrain [57] by using Cre-Lox
recombination technology. In this cKO mouse model, locus of
crossover (loxP) sites were inserted either side of Exons 2 and 3 in
one mouse line (fPS1) which was mated with a mouse line in which
790 A. Harper / Biochimica et Biophysica Acta 1802 (2010) 785–795Cre (causes recombination) protein expression was driven by the
CamK2 promoter. Thus in utero the PS1 locus was intact and the mice
survived to term. Only when the CamK2 promoter became active, at
approximately the third postnatal week, was the Cre protein
expressed causing the loxP sites to recombine and excise Exons 2
and 3 of the PS1 locus, thus progressively removing PS1 protein
expression.2.3. Knockin of exogenous DNA into an endogenous gene
Knockin (KI) mice are similar to knockout mice and are generated
using identical technology. In knockout mouse models the intervening
sequence (IVS) is irrelevant to the gene of interest however in KI mice
the IVS is often relevant and is designed to be transcribed by the
endogenous promoter. An example of such a model is the introduction
of a mutation into the endogenous mouse genomic DNA sequence. The
mutation is introduced using homologous recombination as described
for knockout mice and is introduced into the host mouse genome using
precisely the same techniques (Fig. 2b). Anexample of this technology is
anAPPNLh/APPNLhKImousemodel inwhich gene-targeting strategywas
used to introduce the Swedish familial ADmutations and convertmouse
Aβ to the human sequence [58]. This strategy allowed the neuropath-
ological consequences of human Aβ overproduction to be evaluated
longitudinally in the absence of potential mitigating effects of APP
overexpression or presence of themouse Aβ peptide. A further example
of this technique is a mutant leucine-rich repeat kinase 2 (LRRK2) KI
mouse model. Inherited mutations in LRRK2 are a common genetic
cause of Parkinson's disease and the R1441C mutation in LRRK2 has
been identiﬁed in PD patients. The R1441C mutation was introduced
into themurine LRRK2 locus byhomologous recombination in ES cells. A
positive selection element comprising the phosphoglycerine kinase
promoter driving expression of the neomycin resistance gene (PGK-
neo),ﬂanked by LoxP sites (known as aﬂoxedPGK-neo),was excised by
transient transfection of Cre-expressing plasmid into the ES cells so as
not to interfere with LRRK2R1441C expression. Positive ES cell clones
were injected into host C57Bl/6 blastocysts and progeny tested for
inclusion of the mutation. The LRRK2R1441C KI mice exhibited impaired
dopaminergic neurotransmission which may represent pathogenic
precursors preceding dopaminergic degeneration in PD patients [59].
Interestingly when transgenic (Tg) mice expressing LRKK2R1441G were
generated using a mutated bacterial artiﬁcial chromosome (BAC) they
developed aphenotype that recapitulated cardinal features of PD [60]. In
contrast to the LRRK2R1441C KI mice, these mice had deﬁcits in
locomotion, dendritic degeneration of dopaminergic neurons and tau
phosphorylation. The authors attribute phenotypic differences in the
twomutant R1441 LRRK2mousemodels to higher expressionofmutant
human LRRK2 and endogenous LRRK2 in the BAC Tg mice, background
strain differences (B6/129 in KI mice and FVB in BAC Tg Mice) and the
speciﬁc mutations used (R1441C and R1441G). KI mouse models often
have utility in generating subtle, progressive phenotypes thatmaymore
accurately reﬂect the development of a chronic neurodegenerative
human disorder.
This KI technology has also enabled the development of a new
generation of mouse models in which a speciﬁed endogenous locus is
targeted to allow expression of the gene of interest. This method
allows for stable, single copy gene integration at a known locus. A
bigenic mouse model of AD incorporating CAMK2 promoted APPswe/
lon and Tau301L/406W mutant transgenes was generated by knocking
into the HPRT locus. This model was crossed with a human PS1
transgenic mouse line to generate a trigenic mouse model named
PLB1 [61]. The proposed advantage of such a model is that it provides
a more subtle phenotype when compared to existing models
generated by pronuclear injections or cross-breeding and the model
is not hampered by transgenic procedure-related and disease-
unrelated alterations.3. Acquired mouse models
Mouse models expressing a phenotype that is acquired from direct
manipulation and do not transmit the phenotype from generation to
generation can be classiﬁed not by the heritable genotype they carry but
by the phenotype they produce. The major advantage of these models is
the broadnature of thephenotypesproduced that are simplynot possible
to model using gene engineering. Progressive neurological disorders
often have an impact on speciﬁc neuronal substrates at different stages of
the disorder. Thus a clear understanding of the neuropathology and
molecular mechanism underlying the disease to bemodelled is essential
when generating acquired mouse models of neurological disorders. This
targeting primarily takes the form of direct interference with a speciﬁc
CNS structure via a selective physical lesion or global interference with
the CNS via systemic pharmacological administration.
3.1. Central injury models
The mouse brain is small when compared to other pre-clinical
species however skilled neurosurgeons can target neuronal substrates
in the mouse brain with a high level of accuracy and deliver models
that reproduce particular aspects of a disease. Resources such as the
Atlas of the Mouse Brain [62] or the Allen Mouse Brain Atlas [63]
provide valuable neuro-anatomical maps making such precise lesions
possible. It is important to note that, while different laboratories
publish results using a particular lesion model, the exact method of
inducing the model including the materials and substances used, the
concentration, formulation, duration and route of administration of
the toxin and the mouse strain used all have a bearing on the
reproducibility of the model.
Excitotoxic lesions are derived from neuronal exposure to high
concentrations of glutamate (or glutamate analogues such as NMDA,
ibotinic acid) interacting with its selective membrane receptors. Gluta-
mate receptors can be divided into either G protein coupled (metabo-
tropic receptors) or cation channel coupled (ionotropic receptors)
receptors. Ionotropic glutamate receptors can be further divided into
three major types named after their selective agonists: N-methyl-D-
aspartate (NMDA),α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA) and kainate receptors. Once activated, these receptors produce
neurotoxicity by inducing a massive intracellular inﬂux of Ca2+ which
can activate a number of biochemical pathways leading to irreversible
alterations andultimately cell death [64].Glutamate receptor ionchannels
are expressed throughout the mouse CNS as in all mammals [65]. While
gene engineering has been used to manipulate the levels of glutamate
receptors in vivo [66], the application of exogenous non-competitive
antagonists of glutamate NMDA receptors, for example phencyclidine
(PCP), ketamineanddizocilpine, hasbeenused tochangebothhumanand
animal behaviour and induce schizophrenia-like phenotypes [67].
Interestingly antagonism of NMDA receptors (NMDAR) in a chronic, low
dose PCP treatment regime in C57Bl/6 mice led to a consistent
impairment in spatial learning and working memory without any
apparent sensorimotor impairments [68]. This has been proposed as a
mouse model of the cognitive deﬁcits seen in schizophrenia patients,
however asmore is understoodabout the functionofNMDAR indisturbed
cognitive function then itmay prove useful inmodelling the expression of
cognitive decline in other disorders.
Neurodegeneration is a key diagnostic feature of AD and while
several neural networks contribute to the AD phenotype [69], the
hippocampus and para-hippocampal formations are speciﬁcally
implicated in short-term memory both in AD and in normal aging
[70]. As in transgenic mouse models that target overexpression of the
Αβ peptide to the hippocampus, a physical lesion of the structure
would also be expected to lead to impaired memory function. This
was found to be the case when selective memory deﬁcits were found
in different strains of mice with hippocampal lesions [71]. Such
lesions are produced with stereotaxic surgery, whereby predeﬁned
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and are used to orientate themouse brain with respect to these visible
skull landmarks. This allows very precise delivery of cytotoxic
molecules to the speciﬁed brain region (Fig. 3a). Using this technology
NMDA was delivered to the hippocampus of 12-week-old mice
(Fig. 3b) to generate a hippocampal lesion mouse model in which all
of the hippocampus and dentate gyrus except the most ventral
portions were removed. These mice had impaired spatial cognition
but were spared on non-spatial tasks [72].
Intact NMDAR function is essential for spatial learning and memory
and for hippocampal synaptic plasticity [73]. In addition alteredNMDAR
function has been linked to the pathways that underlie the Aβ
modulated disruption of long term potentiation in the hippocampus
[74]. In aging, it has been suggested that it is NMDAR function, receptor
subunit composition, and/or the environment in which the receptor
interacts in the hippocampuswhich contribute to memory decline [75].
Basedon the importance of theNMDAR inhippocampal function,mouse
models in which NMDAR function is manipulated would be potential
usefulmodels of impairedmemory. A comprehensive comparison of the
behavioural effects of eightNMDAR antagonists in the rat found that the
NMDA antagonists tested produced very diverse effects on the
expression of instrumental action, from a basic ability to respond on
one lever for reinforcement to the ability to respond conditionally on
response alternatives associated with different reward probabilities.Fig. 3. Representation of key structures used to generate acquired mouse models.
(a) Schematic diagram of a mouse skull showing a plan view of the external orientating
features of Lambda and Bregma in context of the eye sockets and sagittal suture.
(b) Schematic diagram of the mouse brain showing a transverse section through the
brain to illustrate key brain areas and the needle positioning required to deliver a toxic
insult to the hippocampus. Dotted line indicates the approximate location of the
transverse section of the brain represented in 3b. Figures reproduced with permission
from The Mouse Brain in Stereotaxic Coordinates, Franklin & Paxinos, 3rd Edition, page
IX and plate 48. (C) Elsevier 2008.Other aspects of responding were left intact but based on these ﬁnding
the authors suggest caution when using NDMARs to model psychoses
such as those seen in schizophrenia [76].
3.2. Peripheral injury models
Spatial learning is impaired following controlled cortical impact in the
mouse as a model of traumatic brain injury [77]. The neurobiology
underlying this model has a signiﬁcant inﬂammatory component. This
brain inﬂammatory response has provided a mouse model of neuroin-
ﬂammation useful for investigating the consequences of head trauma and
stroke in humans [78]. Increased cytokine expression can be achieved in
transgenic mouse models [79]. However the known limitations of
developmental expression of such transgenes and the multitude of
coincident CNS responses during ischemic brain degeneration [80] or
cerebral trauma mean they are more comprehensively modelled in an
acquired mouse model. Interestingly recent studies have indicated that
the mediators of neuroinﬂammation following ischemic brain injury
stimulate amyloid precursor protein metabolism by upregulation of β-
secretase and therefore are able to establish a vicious cycle linking key
components of AD with brain ischemia and neuroinﬂammation [81].
CNS inﬂammation and demyelination are seen in the experimental
autoimmune encephalomyelitis (EAE) model of multiple sclerosis
(MS). This model requires peripheral administration of myelin
antigens emulsiﬁed in adjuvant to elicit a T-cell-mediated immune
response. It is characterised by CNS inﬂammation targeting the spinal
cord leading paralysis, initially in the hind limbs and progressing to
the forelimbs [82]. Different mouse strains and different antigen
combinations can be used to elicit different levels of inﬂammation and
demyelination. Systematic immuno- and histopathological compar-
isons of popular mouse EAE models on the C57Bl/6 background have
been used to advance understanding of the complexity of MS.
Speciﬁcally antigens comprising myelin basis protein–proteolipid
protein (MBP–PLP) fusion protein (MP4)-, myelin oligodendrocyte
glycoprotein (MOG) peptide 35–55- and PLP peptide 178–191-
induced onset of EAE with 6, 12 and 15 days respectively. The reason
for these differences is unclear, though CD8+ T-cell could play an
important role [83]. In addition to the immunological differences the
behaviour of EAE mice has been studied to further understand the
behavioural phenotypes seen in MS patients. When EAE was induced
in SJL mice sickness behaviour symptoms including anorexia, loss of
bodyweight, reduced social exploration, and decreased preference for
sucrose solution were measured. These symptoms were most
prevalent during the acute phase of the disease but abated in later
phases and recovery of these symptoms preceded recovery from other
neurological symptoms. It was suggested that these behavioural
readouts could be used as amodel of the symptoms of depression seen
in MS patients [84].
3.3. Locomotor and dyskinesia models
Parkinsonism can be induced in rodents by direct intracerebroven-
tricular infusion of the dopaminergic/noradrenergic selective neurotoxin
6-hydroxydopamine (6-OHDA) into the substantia nigra [85]. While this
model has been developed inmice [86], it hasmore commonly been used
in rats to good effect when studying the locomotor disturbances seen in
PD patients [87]. Interestingly infusion of 6-OHDA in neonatal rat pups
generates a model of Lesch–Nyhan syndrome, an inherited disorder
caused by a deﬁciency of the enzyme hypoxanthine-guanine phosphor-
ibosyltransferase. The neurological symptoms are similar to those seen in
Huntington's disease and include facial grimacing, involuntary writhing,
and repetitive movements of the arms and legs. Another method of
modelling the dopaminergic depletion seen in PD is to give a
subcutaneous dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). MPTP is a lipophilic molecule that crosses the blood brain
barrier where is it metabolised to generate the neurotoxin 1-methyl-4-
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phosphorylation in mitochondria and selectively kills dopaminergic cells
of the substantia nigra [88]. This preclinical model is also useful to assay
potential treatments for PD.
Psychotic patients receiving long term neuroleptic treatment go on
to develop tardive dyskinesia (TD) in 15-20% of cases. TD is
characterised by repetitive involuntary facial movements that can
persist after treatment has ceased. This oral dyskinesia can bemodelled
in the rat by subcutaneous treatment with the catecholamine depleting
agent, reserpine [89]. Increased chewing, twitching and tongue
protrusion are quantiﬁable features of the robust phenotype in this
model and it is used to investigate the effects of potential therapies for
Parkinson's disease as dopamine antagonists alleviate the TD seen in
patients on chronic neuroleptic treatment and TD is indistinguishable
for the L-Dopa induced dyskinesia seen in Parkinson's disease patients.
Administration of the D2 antagonist spiroperidol dose dependently
blocks the dyskinesia [89],mimicking the effect of L-dopa in PDpatients.
This model is used in mice to show that the atypical neuroleptic
respiridone, successfully reversed reserpine or haloperidol induced
oral–facial movements [90] in linewith clinical studies in schizophrenic
patients. Interestingly the γ-aminobutyric acid (GABA) B agonist
Baclofen also abolished reserpine induced oral facial movements
reinforcing the GABAergic involvement in hypofunction of this aspect
of TD [91].
Further evidence of GABAergic involvement in oral–facial dyski-
nesias has been observed in the Huntington disease research [92].
Oral–facial dyskinesias were observed when rats were treated with
the mitochondrial toxin 3-nitropropionic acid (3-NPA) which also
produced a preferential degeneration of medium-sized spiny GABAer-
gic neurons but spared interneurons and afferents, as observed in
HD striatum. Huntingdon's disease (HD) is a good example of a disease
which has been modelled in both an acquired mouse model and in a
heritable mouse model. The R6/2 mouse model as described in Section
3.1 has been generated to reproduce the pathological features of HD. 3-
NPA is an irreversible suicide inhibitor of the mitochondrial enzyme
succinate dehydrogenase (SDH). This enzyme forms part of the
mitochondrial electron transport chain and 3-NPA acts to cause acute
metabolic stress and subsequent cell death. Systemic administration of 3-
NPA leads to localised striatal neurodegeneration with a preferential loss
of (GABA)ergic spiny projection neurons mimicking features of HD [93].
Acevedo-Torres et al used Quantitative Polymerase Chain Reaction to
comparemitochondrial damage in the striatumof 3-NPA treated animals
with that of the R6/2 transgenicmouse line and found increased damage
compared to nuclear DNA in both models [94]. The mechanisms
underlying striatal vulnerability in HD are unknown [95], but these
models serve as important examples of how heritable and non heritable
approaches can synergise to help to understand a disease pathology.3.4. Models of psychoses
In rodents attenuation of the startle response by Pre-Pulse Inhibition
(PPI) is used as a model of sensory motor gating mechanisms in the
brain.Human schizophrenic patients have an impaired PPI response and
thus the rodent PPI model is often used to investigate the effects of
potential novel therapeutics, often in combination with glutamatergic
receptor blockade [96,97]. It has been shown that rat pups removed
from theirmother for 1 day at post natal day (PND) 6 or 9 had a reduced
PPI response associated with hyperactivity of the dopaminergic system
involving the hypothalamic-pituitary-adrenal (HPA) axis [98]. The
disturbances in the HPA system, the dopamine system, hippocampus
and long-term behavioural effects modelling deﬁcits seen in mental
patients led the authors to propose 24 hrmaternal deprivationmodel to
be a “schizophrenia-like” neuro-developmental animalmodel [99]. This
maternal separationmodel has been extended tomicewhere decreased
anxiety, learning and memory dysfunction, deﬁcits in behaviouralﬂexibility aswell as a 20% loss of neurons in the dentate gyruswere seen
in PND 9 pups subjected to a single 24-h maternal separation [100].
3.5. Gene silencing by RNA interference
Rather than engineering an endogenous gene locus to lower or
remove the expression of a particular gene of interest, protein expression
from an intact gene can be prevented by interfering with the RNA
generated from the transcribedDNA. During protein production, typically
DNA is transcribed into a speciﬁc type of RNA that codes for the gene
called messenger RNA (mRNA). This mRNA is then translated into a
primary protein within ribosomes in the cell. This primary protein is
subjected to a series of post-translational modiﬁcations to become a
functional protein. RNA interference (RNAi) is a useful technique to
provide amodel inwhich themRNA transcribed from the gene of interest
is targeted with exogenous RNA administration. First demonstrated in
Caenorhabditis elegans [101], RNAi works when exogenous double
stranded RNA (dsRNA) is introduced into the host cells where it acts to
destabilise or degrade targeted complementary mRNA, thereby effec-
tively silencing targeted gene expression. One promising use for this
technology is systematic large scale RNAi silencing of the genes in a
molecular pathway of interest and examining the effect on downstream
gene expression. Further work has identiﬁed micro RNAs (miRNAs)
which regulate endogenous gene expression and in vertebrates are
thought to comprise 1%of animal genes [102]. ThesemiRNAs can regulate
the expression of hundreds of RNAs and several have been shown to be
associated with different neurological disorders and even subtle changes
in neuronal organisation can impact on cognitive and psychological
functions [103]. As a method of manipulating gene expression this
technology represents an advantage over engineering the endogenous
genome as much of the work is completed in vitro and delivered to the
adult mouse to generate the model. Extensive breeding and genotyping
regimes are not required, though themanipulation is not carried through
the germ line.
4. The problem with mice
When describing mouse models the impact of the background strain
on which the relevant model is generated is a key consideration. For
acquired mouse models the choice of mouse strain is important though
previous characterisation of different mouse strains can provide a guide
for subsequent experiments. As an example four different mouse strains
responded with very different behavioural responses and showed
variable responses to CNS injury when kainic acid was infused into the
CNS [104]. Interestingly, of those tested, only the FVB/N mouse strain
showed apparent spatial learning and memory deﬁcits following CNS
lesion andyet, as the authors note, the FVB/Nmouse strain is almost blind
[105] making data generated from most visual based behavioural tasks
un-interpretable for this strain. Even within a single mouse background,
strain phenotypic differences can depend on the precise nature of the
model. In evaluating 4mousemodels of Diabetic Neuropathy (DN), all on
a C57Bl/6 background strain, different responses were recorded when
diabetes was induced. Diabetes was conﬁrmed in mouse models of
streptozotocin (STZ)-induced diabetes, spontaneous type 1 diabetes
[B6Ins2] and 2 models of spontaneous type 2 diabetes [B6-db/db, BKS-
db/db] diabetes. Despite persistent hyperglycemia, the STZ-treated and
B6Ins2 mice were resistant to the development of DN. In contrast DN
developed in both type 2 diabetes models though the B6-db/db mice
required an increased fat diet while the BKS-db/db mice developed
severe DN and remained hyperglycemic on standard mouse chow [106].
In addition when different mouse strains were exposed to a middle
cerebral artery occlusion, differences in susceptibility to cerebral ischemia
were found to be related to different cerebral vascular anatomy in the
wild type mouse lines tested [107]. Thus when a novel mouse strain is
used to generate an acquired mouse model which may be subjected to
behavioural characterisation, it is prudent to evaluate the physical
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SHIRPA [108] which has shown clear strain differences in all of the levels
of platform phenotyping [109].
Further considerations to be aware when embarking on a mouse
model research effort include the health status of the mouse colony,
husbandry practices, the environment inwhich themicearemaintained
and the breeding history of the colony. Most animals suffer from
infections at some time in their life however pathogenic infections can
have a signiﬁcant impact on mouse models, particularly chronic
neurodegenerativemodels or thosewith adepressed immune response.
While biological research facilities aim to keep animals in top health
conditions, outbreaks of infection do occur and the decision as to
whether or not to cull existing mouse models is a difﬁcult one,
particularly heritablemodelswhere rederivation into a clean area of the
facility can be very costly and have amajor impact on project timelines.
Quantifying the beneﬁts of maintaining a clean colony is difﬁcult
however the Mary Lyon Centre (MLC) of the Medical Research Council
(MRC) Harwell reported on the outcome of a 30-month programme to
rederive 310 speciﬁc pathogen-free mouse strains. The MLC used
embryo rederivation and hysterectomy performed in isolators to
facilitate the containment and decontamination of twomouse hepatitis
virus (MHV) infection outbreaks. Rederivation of the colony eliminated
a number of viral, worm, protozoan and mite infection. The improved
microbiological status yielded notable beneﬁts for mouse health and
welfare and the science at MRC Harwell. Among several improvements
early weight loss associated with inﬂammatory bowel disease in a
mousemodel ofHuntington's disease and earlyweight loss inmalemice
mutagenised with ENU were markedly reduced or eliminated [110].
Animal husbandry practices can combine with background strain to
impact on such conditions as environment enrichment [111], noise
levels [112] and while decreased stocking density may have a negative
impact [113], increased stocking density may not be an issue [114].
Maintenance of colony records is standard husbandry practice in large
mouse breeding establishments but often smaller breeding efforts do
not keep adequate records. This is crucial in avoiding problems with
maintaining the colonyof a heritablemousemodel as it is all too easy for
genetic drift or inbreeding depression to inﬂuence to breeding
performance of the colony [115]. The key is to be aware that the
inﬂuence of these factors on the phenotype of mouse model under
consideration and control for them appropriately.
5. Summary
Making mouse models of human neurological disorders incurs a
signiﬁcant investment of resources for any research organisation. The
return on this investment is a deeper understanding of the disorder
aetiology and/or a preclinical model that is effective in predicting a
clinical outcome for a given therapeutic agent. Pre-clinical models of
disease need to be readily available, robust and develop the desired
phenotype relatively rapidly. Chronic mouse models, particularly of the
cognitive deﬁcits observed in neurodegenerative disorders, may take
several months or years even, to display a robust phenotype. As such,
when considered in a pharmaceutical industry setting, these chronic
models are simply impractical for use in screening the efﬁcacy of
potential therapeutics. Thus mouse models with a rapidly expressed
phenotype aremore suitable as pre-clinical models and popularmodels
are those with non-behavioural readouts in genetically altered mouse
models or acute responses in acquired mouse models.
The extensive library of mutant mouse models will continue to
expand as new molecules linked to speciﬁc disease are discovered and
ever more elegant methods of controlling elevated or depleted gene
expressionaredeveloped.Aswithanygood research thekey requirement
of adequate experimental controls will become more relevant as more
laboratories access this powerful technology to generate their own
models and the potential for false positive results is increased. Conversely
as multiple research centres conduct experiments on existing mousemodels and provide further validation with positive data derived from
different research institutes, then the model in question gains in trust
among investigators as a compelling model of the relevant disease
phenotype. Similarly as the basic neurobiology of disparate neurological
disorders is revealed common molecular pathways are likely to become
clearer. Once initiated by a diagnostic lesion,many neurological disorders
have failures in common transmitter neuronal systems that are amenable
to testing in acquired mouse models.
Mouse models of neurological disorders are produced because
they are amenable to treatments with potential therapeutic agents.
As heritable mouse models more accurately reproduce the speciﬁc
lesions seen in a wide variety of diseases, they are more relevant in
a research effort employing a disease modiﬁcation strategy.
Acquired mouse models are often not designed to reproduce
neurological lesions but model failures in the underlying neuro-
transmitter systems concurrent in a range of disease. As such they
are more applicable for use in research efforts targeting symptom-
atic therapies. The challenge to mouse modellers is to specify
appropriate background strains and controlled environments in
which to test their favourite model and to publish both the negative
and positive results of such speciﬁcations.References
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